Date: Thursday, May 5, 2016 
Time: 10AM PST | 1PM EST | 6PM GMT
Duration: 1 hour
Complementary and open to life science professionals globally

Click here to register

Overview:

Despite significant advances and increased understanding of the importance of physicochemical properties in drugs and drug candidates, solubility is still the number 1 issue in drug product development.  Approximately 40% of approved drugs and 75% – 90% of developmental pipelines consist of drugs and drug candidates with poorly soluble characteristics, representing a substantial risk to successful drug development.  Remarkably, solubility is one of the properties that can be assessed and addressed early in drug discovery and development, well before candidates are selected or advanced into costly preclinical and clinical development.  In this complimentary live webinar, open to life science professionals globally, WuXi brings together scientific experts in pharmaceutical- and medicinal-chemistry sciences to address strategies in reducing program risk while increasing odds of success by “Tackling the #1 Drug Product Development Problem: Solubility”.

*A recording will be made available after the live webcast – Please register to receive more information.

Speakers:

Mui Cheung, Director, Medicinal Chemistry, GlaxoSmithKline
Manish Gupta, Head of Biopharmaceutics, Platform Technologies & Science, GlaxoSmithKline
Matt Burke, Head of Drug Delivery, Platform Technologies & Sciences, GlaxoSmithKline
Riccardo Panicucci, Vice President, Pharmaceutical Development Services, WuXi AppTec
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (Moderator)

Speaker Bio:

Mui Cheung, Director, Medicinal Chemistry, GlaxoSmithKline

Mui Cheung graduated summa cum laude from Florida A&M University with a B.S. degree in Chemistry in 1993. She received her Ph.D. from Rice University in Organic Chemistry focusing on total synthesis of natural products and synthetic methodology development. Dr. Cheung joined GlaxoWellcome in 1997 as a medicinal chemist and has held increasing leadership responsibility over the years. Dr. Cheung is an accomplished research leader with over 18-year track record of leading large multi-disciplinary and transnational teams to deliver tools, leads and clinical candidates across a variety of therapeutic areas including oncology, urology, metabolic, cardiovascular, inflammation and dermatology. She has led or involved in teams that deliver 15 candidate selections of which six progressed to human clinical trials and one is a marketed product (Votrient®). Dr. Cheung is co-inventor of 59 NCE patents (29 issued US patents) including Votrient® and has co-authored over 130 publications, presentations and patent applications. Dr. Cheung is currently the Head of Chemistry in the Virtual Proof of Concept (VPoC) Discovery Performance Unit in GlaxoSmithKline and is responsible for managing and supporting a portfolio of early to late stage programs across multiple disease areas.

Manish Gupta, Head of Biopharmaceutics, Platform Technologies & Science, GlaxoSmithKline

Manish Gupta serves as the Head of Biopharmaceutics in the Platform Technologies & Science Department at GlaxoSmithKline. In this capacity, Dr. Gupta leads a global team to improve product design and control across oral, inhalation, and parenteral dosage forms based on the foundation of biopharmaceutics understanding. Prior to his current role, Dr. Gupta led a project team for a transformational asset to design a novel long acting parenteral product with the right balance between biopharmaceutics, stability and manufacturability. He has made significant scientific and leadership contributions towards successful commercialization of three oral products: Tykerb, Votrient, and Mekinist. Dr. Gupta has championed science and risk based product development approach for GSK’s first QbD file, Votrient, with extensive regulatory engagement. He received his Ph.D. from University of Connecticut studying amorphous systems.

Matt Burke, Head of Drug Delivery, Platform Technologies & Sciences, GlaxoSmithKline

Matt Burke serves as Head of Drug Delivery in the Platform Technologies & Science Department at GlaxoSmithKline. He leads a group guiding the drug delivery strategy at GSK, which includes internal development and application of technologies to the portfolio as well as external evaluation. Dr. Burke also serves as a project lead for assets in early clinical development and is a master subject matter expert on oral modified release and continuous manufacturing. Dr. Burke has worked at multiple sites in the US and UK within GSK, has approximately 30 articles, patents and symposium presentations. He has served as an adjunct professor at North Carolina State University Biomolecular and Chemical Engineering department and University of North Carolina at Chapel Hill School of Pharmacy and received his PhD in Oral Colonic Drug Delivery Systems.

Riccardo Panicucci, Vice President, Pharmaceutical Development Services, WuXi AppTec

Rick Panicucci joined WuXi AppTec in February 2015. As Vice President of Pharmaceutical Development Services, Dr. Panicucci provides scientific leadership for 160 scientists in Developability, Formulation Development, and GMP Manufacturing and is responsible for the execution of all Parenteral and Oral dosage form programs. He also maintains key client relationships and assesses new technologies through partnering or internal M&A capacity building. In addition to his position at WuXi, he currently serves as an Adjunct Professor at Massachusetts College of Pharmacy. Prior to WuXi, Dr. Panicucci was the Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015. His responsibilities included analytics, solid state chemistry and formulation development of all small molecule therapeutics in early development. He also helped develop novel drug delivery technologies for small molecules and large molecules including siRNA. Dr. Panicucci has also led groups in Formulation and Research and Development at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. His education includes two post doctoral fellowships at University of California at Santa Barbara and the Ontario Cancer Institute. He received his Ph.D. in Physical Organic Chemistry from the University of Toronto.

Richard Soll, PhD, SVP, International Discovery Service Unit, WuXi AppTec

Dr. Richard Soll is Senior Vice President of the International Discovery Service Unit (IDSU) at WuXi AppTec. In this capacity, Dr. Soll leads the discovery synthetic- and medicinal-chemistry global collaborations at WuXi that aim to provide expertise and innovative solutions for small molecule drug R&D across biopharma and life science industries. In addition, Dr. Soll’s expanded responsibilities include oversight of the newly established WuXi offices in Cambridge, Massachusetts and Israel.  These offices bring WuXi’s comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world’s two leading biotech hubs. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals and was trained as a synthetic chemist at Dartmouth and Harvard. Dr. Soll’s drug discovery and development experiences has led to more than 100 patents and papers, and more than 10 drug candidates advancing to the clinic including drugs of breakthrough designation. Dr. Soll has been an SAB member to biotech companies and advisor to entrepreneurs.